BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025
• 2026

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 25
• 26
• 27
• 28
• 29
• 30

• Biotech Beach

  Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - September 15, 2023

  Arcutis Biotherapeutics, Inc., an early commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, reported the grant of an aggregate of 39,000 restricted stock units of Arcutis’ common stock to six newly hired employees.

  September 15, 2023

   · 

  3 min read
• Business

  Nilogen Oncosystems announces new Chief Scientific Officer

  Nilogen Oncosystems, a privately-held biotechnology company dedicated to increasing efficiency and reducing risk in the oncology drug development process, has announced the appointment of its Vice President of Research and Operations, Rikhia Chakraborty, Ph.D., to Chief Scientific Officer.

  September 15, 2023

   · 

  3 min read
• Genetown

  Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - September 15, 2023

  Fulcrum Therapeutics, Inc.®, a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, announced that the company granted non-statutory stock options to new employees.

  September 15, 2023

   · 

  1 min read
• Job Trends

  Ojjaara (momelotinib) approved in the US as the first and only treatment indicated for myelofibrosis patients with anemia

  GSK plc announced that the US Food and Drug Administration has approved Ojjaara for the treatment of intermediate or high-risk myelofibrosis, including primary myelofibrosis or secondary myelofibrosis, in adults with anemia.

  September 15, 2023

   · 

  15 min read
• BioCapital

  Dr. Amir Bajoghli and Skin & Laser Dermatology Center Introduce Candela VBeam Perfecta for Advanced Port Wine Stain and Birthmark Removal Treatment

  Dr. Amir Bajoghli and the Skin & Laser Dermatology Center proudly unveil the Candela VBeam Perfecta treatment, the latest generation of pulse dye laser technology for port wine stain and birthmark removal.

  September 15, 2023

   · 

  2 min read
• Biocytogen Officially Launches RenMice® Series

  Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”, HKEX: 02315) officially announces the RenMice® series, which includes a collection of independently developed, fully human antibody mice and TCR mice with proprietary intellectual property.

  September 15, 2023

   · 

  8 min read
• First Wave BioPharma To Present at the BIO Investor Forum

  First Wave BioPharma, Inc., (NASDAQ:FWBI), (“First Wave” or the “Company”) today announced that James Sapirstein, President and CEO, will make a company presentation at the BIO Investor Forum being held October 17-18, 2023, at the Hilton San Francisco Union Square in San Francisco.

  September 15, 2023

   · 

  3 min read
• Biotech Bay

  PhenomeX Unveils Meteor™ Chips For Quantitative Bulk Analysis On The IsoSpark™ Platform To Revolutionize High Throughput Multiplexed Hands-Free Proteomics

  PhenomeX Inc., the functional cell biology company, announced the launch of Meteor™ chips on the IsoSpark™ platform, providing a significant advancement in high throughput, quantitative, fully automated, multiplexed bulk proteomics. ™.

  September 15, 2023

   · 

  4 min read
• Licensing agreement announced between Inoviq and ResearchDx to offer EXO-NET exosome isolation and diagnostic development services in the US

  ResearchDx Inc (ResearchDx), a premier Contract Diagnostics Organization (CDO) offering complete in vitro diagnostic (IVD) services and INOVIQ Limited (INOVIQ)

  September 15, 2023

   · 

  1 min read
• Business

  Integrated BioPharma Reports Results for its Quarter and Fiscal Year Ended June 30, 2023

  Integrated BioPharma, Inc. reports its financial results for the quarter and fiscal year ended June 30, 2023.

  September 15, 2023

   · 

  5 min read